The oncology impact of highly active antiretroviral therapy

Journal of Oncology Pharmacy Practice

Volumn 13, Issue 1, 2007, Pages 17-25

  Schlichemeyer, Richard ^a   Chambers, Carole ^b,d   Gill, M John ^c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Alberta Cancer Board ^*  (Canada)

^c Southern Alberta Clinic   (Canada)

^d TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Chemotherapy costs; HAART; HIV malignancies

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANADA; CANCER INCIDENCE; CANCER PATIENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA BASE; DRUG COST; DRUG MEGADOSE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; ONCOLOGY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; STANDARDIZATION;

ALBERTA; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; NEOPLASMS; PREVALENCE;

EID: 34250204554     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206074045     Document Type: Article

References (14)

1. Yarchoan R, Little RF. AIDS-related malignancies. In DeVita VT Jr, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology, seventh edition. Lippincott Williams & Wilkins, 2005: 2247-62.
2. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6: 99-106.
3. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468-76.
4. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
5. Gingues S, Gill MJ. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Med 2006; 7: 1-9.
6. Nguyen LM, Khartchenko A, Chambers C, Bhanji A, May N, Gill MJ. Chemotherapy treatment costs of AIDS-related malignancies. Can J Hosp Pharm 1997; 50: 209-17.
7. Monfardini S. Neoplastic complications of AIDS. In Peckman M, Pinedo HM, Veronesi U eds. Oxford textbook of oncology, Volume 2. Oxford University Press Inc., 1995: 1895.
8. Moore DF Jr, Mitsuyasu RT. AIDS-associated malignancies. In Pazdur R ed. Medical oncology: a comprehensive review. PRR Inc., 1993: 381-93.
9. Sharpe M, Easthome SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002; 62: 2089-126.
10. Northfelt DW, Dezube Bj, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445-51.
11. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. AIDS Malignancy Consortium. J Clin Oncol 2001; 19: 2171-78.
12. Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-63.
13. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004; 4: 861-75.
14. Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma; AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 1538-43.